Navigation Links
Reportlinker Adds Triple Analysis: Leukemia, Pancreatic Cancer and Prostate Cancer
Date:5/3/2011

NEW YORK, May 3, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Leukemia, Pancreatic Cancer and Prostate Cancer

http://www.reportlinker.com/p0284699/Triple-Analysis-Leukemia-Pancreatic-Cancer-and-Prostate-Cancer.html

This triple analysis focuses on cancer drug development strategies in Leukemia, Pancreatic Cancer and Prostate Cancer. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia

The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer

The pancreatic cancer report part comprises defined and up to date development strategies for 213 pancreatic cancer drugs within the portfolio of 137 investigators, from Ceased to Marketed. This report part extensively analyses 171 identified targets of pancreatic cancer drugs, organized into 142 drug target profiles, and assesses them in pancreatic cancer.

This part is based on the following publication:

Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?

Part III: Prostate Cancer

The prostate cancer report part comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. This report part extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia

5.1 The Scope of this Report 29

6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443

7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727

8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728

9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129

11 Disclaimer 1130

12 Drug Index 1131

13 Company Index 1140

Figures: Includes 6 Figures

Tables: Includes 253 Tables

Total Number of Pages: 1,147

Part II: Pancreatic Cancer

5.1 The Scope of this Report 24

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (171 Drug Targets) 28

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Pancreatic Cancer Therapeutic Pipeline? (142 Drug Target Strategies and 213 Drugs) 333

8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 374

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Pancreatic Cancer Therapeutic Pipeline by Investigator (137 Investigators) 408-599

11 Drug Index 601

12 Company Index 606

Figures: Includes 5 Figures

Tables: Includes 193 Tables

Total Number of Pages: 610

Part III: Prostate Cancer

5.1 The Scope of this Report 28

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (202 Drug Targets) 32-383

7 Emerging New Products to Established Ones: Drug Target Strategies by their Highest Stage of Development in the Prostate Cancer Pipeline (187 Drug Target Strategies and 346 Drugs) 384-438

8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 439-485

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Prostate Cancer Therapeutic Pipeline by Investigator (198 Investigators) 486-820

11 Drug Index 822

12 Company Index 831

Figures: Includes 6 Figures

Tables: Includes 257 Tables

Total Number of Pages: 838

To order this report:

: Triple Analysis: Leukemia, Pancreatic Cancer and Prostate Cancer

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Cancer Reports Bundle
2. Reportlinker Adds Medical Imaging Technologies for Oncology Diagnostics: The Global Market
3. Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies
4. Reportlinker Adds Advanced Lung Cancer in Patient Smoker with Squamous Cell: Clinical Insights from a US Oncologists Survey
5. Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma
6. Reportlinker Adds Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview
7. Reportlinker Adds Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify
8. Reportlinker Adds Pharmaceutical Key Trends 2011 - Biosimilar Market Overview
9. Reportlinker Adds Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry
10. Reportlinker Adds Forecast Insight: Antibacterials
11. Reportlinker Adds Global Cardiovascular Surgery Devices Market Trends and Future Forecast (2009 - 2014)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Feb. 22, 2017  Corin Group announced today the ... used to treat patients with both a massive rotator ... The condition, known as cuff tear arthropathy, causes pain ... The Humelock Reversed Shoulder System, which was ... company based near Lyon, France , ...
(Date:2/22/2017)... Research and Markets has announced the addition of the ... to their offering. ... Dermatological conditions are one of the most ... US population suffers from at least one active skin condition. ... has remained saturated with established and generic products. However, the ...
(Date:2/22/2017)... 22, 2017 Research and Markets has ... by Drug Molecule (Biologic, Small Molecule Drugs), By Route of ... Blockers) Outlook 2022" report to their offering. ... The global psoriasis ... 2016-2022 This report provides a detailed analysis of ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Forty-five percent ... those report that family members or friends have also commented about their poor ... loss wear hearing aids. One reason, suggested by 89 percent of American respondents, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Super-Sod will attend the ... event in Athens, Georgia. , A shift from Super-Sod’s simple Athens Home Show booth ... For the booth, grass seed plant manager Chris Roquemore constructed furniture from recycled pallet ...
(Date:2/22/2017)... Troy, NY (PRWEB) , ... February 22, 2017 , ... ... effort — especially for hospitals and health systems. Smith & Jones’ delves into this ... In this episode, President of Smith & Jones David Vener meets up with social ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, ... Center on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar ... in our community. We are thrilled to participate in this event because we believe ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a ... that the patient context (age, illness and life choices) should be dissociated from ... occurrence. In addition, all too often, studies regarding health system performance ...
Breaking Medicine News(10 mins):